Esperion Settles Patent Litigation With Aurobindo Pharma; Generic Launch Delayed to 2040

Esperion Therapeutics, Inc. announced a settlement agreement with Aurobindo Pharma Limited resolving patent litigation concerning generic versions of NEXLETOL and NEXLIZET. Under the agreement, Aurobindo will not market generic versions of these drugs in the U.S. before April 19, 2040, unless certain conditions are met. The company's patent litigation against other defendants, including MSN Pharmaceuticals Inc. and Sandoz Inc., remains active. Esperion is a biopharmaceutical company developing and commercializing therapies for cardiometabolic and rare/orphan diseases.